XSHE
002099
Market cap1.49bUSD
Oct 09, Last price
6.32CNY
1D
2.76%
1Q
20.61%
Jan 2017
-25.47%
IPO
131.93%
Name
Zhejiang Hisoar Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
5.50
EPS
—
Div yield, %
—
Shrs. gr., 5y
-1.28%
Rev. gr., 5y
-5.52%
Revenues
1.86b
-4.01%
Net income
-91m
L-72.42%
CFO
-60m
L
Dividend
May 24, 20230.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Hisoar Pharmaceutical Co., Ltd. is a pharmaceutical enterprise that specializes in the manufacturing and global distribution of fine chemicals and specialized active pharmaceutical ingredients (APIs). Its diverse product portfolio encompasses materials used in the production of antibiotics, antiviral medications, cardiovascular drugs, and glucose-reducing agents, among others. Beyond these core APIs, the company also supplies pharmaceutical intermediates and provides customized processing services. Key products include clindamycin, the 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, and voglibose. A significant portion of its output is destined for international markets through exports. Established in 1966, the company maintains its operational headquarters in Taizhou, China.
Key people
Bing Yao
Chief Financial Officer, Deputy General Manager, Secretary of the Board, Director · since 2025
Guangshun Chen
Deputy General Manager, Director · since 2025
Minjie Chen
Staff Elected Director · since 2025
Fangqi Chen
Director · since 2025
Yangchao Wang
Chairman of the Board · since 2019
Guorui Xu
General Manager, Director · since 2022
Chao Liang
Independent Director · since 2022
Jianmin Qian
Independent Director · since 2022
Yongping Yu
Independent Director · since 2022
Headquarters & legal address
浙江省台州市椒江区外沙支路100号
台州市, ZJ 100000
CN
台州市, ZJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||